Tempus AI (TEM) shares took a hit Monday after the company announced it's buying Personalis (PSNL) in a deal valued at $1.5 billion. The acquisition is all about doubling down on cancer monitoring — specifically, the minimal residual disease (MRD) market, which Tempus says is a $20 billion opportunity.
Here's the gist: Tempus, which uses AI to analyze clinical and molecular data, is buying Personalis, a company that makes ultra-sensitive tests to detect tiny bits of cancer DNA left in the body after treatment. The idea is that catching that "minimal residual disease" early can help doctors decide if a patient needs more treatment — and that's a huge and growing market.
The Deal Details
The transaction values Personalis at $1.5 billion enterprise value, net of Tempus' existing ownership stake. Personalis shareholders will get $16.25 per share, which is a 6% premium over Friday's closing price and a 28% premium to the 30-day volume-weighted average price before the deal was announced.
Tempus will pay mostly in stock, but it can use cash for up to 50% of the consideration. As of March 31, Tempus had $521.17 million in cash and equivalents, so it's got some dry powder. The exchange ratio is capped at 0.3356 shares of Tempus common stock per Personalis share.
Personalis reported preliminary Q2 revenue of $22.4 million, with test volumes up 33% year-over-year. Not bad for a company that's still early in its commercial journey.
Why This Makes Sense
Tempus CEO Eric Lefkofsky said the deal builds on an existing partnership that started in November 2023. "Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure," he said. "With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."
Personalis CEO Chris Hall echoed the sentiment, saying the combined resources will accelerate innovation and deliver value to patients and shareholders.
The acquisition is expected to close in late 2026 or early 2027.
Tempus Earnings on Deck
Investors are also looking ahead to Tempus' earnings report on July 30. Analysts expect a loss of 20 cents per share, narrowing from a loss of 22 cents a year ago. Revenue is forecast at $380.24 million, up from $314.63 million.
Wall Street remains bullish on Tempus. The stock has a Buy consensus with an average price target of $66.82. Recent analyst moves include Guggenheim raising its target to $65 on July 16, Freedom Capital Markets initiating with a Hold and $59 target on July 1, and Needham maintaining a Buy with a $75 target on June 1.
Despite the positive analyst sentiment, Tempus shares were down 8.06% at $48.24 at the time of publication Monday. The market seems to be weighing the near-term dilution and integration risks against the long-term potential of the MRD market.
For investors, the key question is whether Tempus can execute on this acquisition and capture a meaningful slice of that $20 billion MRD opportunity. The deal certainly gives it a strong position, but the stock's slide suggests some skepticism about the price tag and the path to profitability.
